FDA Approves Riociguat (Adempas) for PAH and CTEPH
News of the approval comes within weeks of an announcement that the drug would be granted 2 separate orphan-drug designations.
medscape.com
FDA Approves Macitentan (Opsumit) for PAH
This is the second agent for pulmonary arterial hypertension this month, following the approval of riociguat October 8.
medscape.com
FDA Clears Selexipag for Pulmonary Arterial Hypertension
medscape.com
FDA: Oral Treprostinil for PAH Rejected Again
Treprostinil, already available in injectable drug and inhaled formulations, has seen mixed success in the FREEDOM trial series.
medscape.com
Implant Eliminates External Pump in Pulmonary Hypertension
FDA Clears Two-Drug Combo as First-Line Treatment for PAH
Ambrisentan plus tadalafil in newly diagnosed pulmonary arterial hypertension reduces risk of disease worsening and improves exercise ability.
medscape.com
While it appears that “2 is better than 1” where treatment of a dismal disease like Pulmonary Hypertension goes, not all combinations are equal. Among combinations of phosphodiesterase type 5 inhibitors with endothelin receptor antagonists, Tadanafil + Ambrisentan works, but not Sildenafil + Bosentan.
Currently, there are five drug classes from which physicians can mix-and-match: prostacyclins, guanylate cyclase stimulators, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, and specific prostacyclin IP receptor agonists. Expect upcoming trials to explore various combinations of these.
Currently, there are five drug classes from which physicians can mix-and-match: prostacyclins, guanylate cyclase stimulators, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, and specific prostacyclin IP receptor agonists. Expect upcoming trials to explore various combinations of these.
